BRIEF-Jade Biosciences Announces First Participant Dosed In First-In-Human Phase 1 Clinical Trial Of Jade201

Jade Biosciences

Jade Biosciences

JBIO

0.00

May 26 (Reuters) - Jade Biosciences Inc JBIO.O:

  • JADE BIOSCIENCES ANNOUNCES FIRST PARTICIPANT DOSED IN FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL OF JADE201, A NOVEL HALF-LIFE EXTENDED AFUCOSYLATED ANTI-BAFF RECEPTOR MONOCLONAL ANTIBODY

  • JADE BIOSCIENCES INC - INTERIM PHASE 1 FIH DATA FOR JADE201 EXPECTED IN 2027

Source text: ID:nGNX1Bm8Cj

Further company coverage: JBIO.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.